Last reviewed · How we verify
Continuous Infusion Remimazolam
Continuous Infusion Remimazolam is a Benzodiazepine Small molecule drug developed by Second Affiliated Hospital of Wenzhou Medical University. It is currently FDA-approved for Procedural sedation and analgesia, ICU sedation. Also known as: Continuous infusion group.
Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.
Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis. Used for Procedural sedation and analgesia, ICU sedation.
At a glance
| Generic name | Continuous Infusion Remimazolam |
|---|---|
| Also known as | Continuous infusion group |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | FDA-approved |
Mechanism of action
Remimazolam potentiates the inhibitory effects of GABA at GABA-A receptors in the central nervous system, leading to sedation, anxiolysis, and muscle relaxation. As a continuous infusion formulation, it provides sustained sedation suitable for procedural or ICU settings. It is rapidly metabolized by tissue esterases, resulting in a shorter duration of action compared to traditional benzodiazepines.
Approved indications
- Procedural sedation and analgesia
- ICU sedation
Common side effects
- Hypotension
- Respiratory depression
- Bradycardia
- Headache
Key clinical trials
- Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
- Effect of Remimazolam on Postoperative Delirium (NA)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Perioperative GDNF as a Predictive Factor for Postoperative Delirium and Adverse Neurological Outcomes in Pediatric Surgery (NA)
- REMIMID-ICU: Remimazolam vs Midazolam for Deep Sedation in Hemodynamically Unstable, Mechanically Ventilated Adults (PHASE3)
- Effect of Remimazolam and Propofol on Hemodynamic Stability in Prone Position (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Infusion Remimazolam CI brief — competitive landscape report
- Continuous Infusion Remimazolam updates RSS · CI watch RSS
- Second Affiliated Hospital of Wenzhou Medical University portfolio CI
Frequently asked questions about Continuous Infusion Remimazolam
What is Continuous Infusion Remimazolam?
How does Continuous Infusion Remimazolam work?
What is Continuous Infusion Remimazolam used for?
Who makes Continuous Infusion Remimazolam?
Is Continuous Infusion Remimazolam also known as anything else?
What drug class is Continuous Infusion Remimazolam in?
What development phase is Continuous Infusion Remimazolam in?
What are the side effects of Continuous Infusion Remimazolam?
What does Continuous Infusion Remimazolam target?
Related
- Drug class: All Benzodiazepine drugs
- Target: All drugs targeting GABA-A receptor
- Manufacturer: Second Affiliated Hospital of Wenzhou Medical University — full pipeline
- Therapeutic area: All drugs in Anesthesia/Sedation
- Indication: Drugs for Procedural sedation and analgesia
- Indication: Drugs for ICU sedation
- Also known as: Continuous infusion group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing